NO20052463L - Nye injiserbare depotpreparater - Google Patents

Nye injiserbare depotpreparater

Info

Publication number
NO20052463L
NO20052463L NO20052463A NO20052463A NO20052463L NO 20052463 L NO20052463 L NO 20052463L NO 20052463 A NO20052463 A NO 20052463A NO 20052463 A NO20052463 A NO 20052463A NO 20052463 L NO20052463 L NO 20052463L
Authority
NO
Norway
Prior art keywords
injectable depot
depot preparations
new injectable
new
viscous
Prior art date
Application number
NO20052463A
Other languages
English (en)
Inventor
Jaymin Chandrakant Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20052463L publication Critical patent/NO20052463L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det er beskrevet et injiserbart depotpreparat som er viskøst, eller blir viskøst in situ, omfattende en oppløseliggjort aryl-heterocyklisk farmasøytisk forbindelse, så som ziprasidon.
NO20052463A 2002-10-25 2005-05-23 Nye injiserbare depotpreparater NO20052463L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42147302P 2002-10-25 2002-10-25
PCT/IB2003/004576 WO2004037289A2 (en) 2002-10-25 2003-10-13 Novel injectable depot formulations

Publications (1)

Publication Number Publication Date
NO20052463L true NO20052463L (no) 2005-05-23

Family

ID=32176718

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052463A NO20052463L (no) 2002-10-25 2005-05-23 Nye injiserbare depotpreparater

Country Status (20)

Country Link
US (1) US20040138237A1 (no)
EP (1) EP1575616A2 (no)
JP (1) JP2006514923A (no)
KR (1) KR20050055781A (no)
CN (1) CN1849110A (no)
AR (1) AR041722A1 (no)
AU (1) AU2003267788A1 (no)
BR (1) BR0315568A (no)
CA (1) CA2503076A1 (no)
MX (1) MXPA05002561A (no)
NL (1) NL1024590C2 (no)
NO (1) NO20052463L (no)
PA (1) PA8586201A1 (no)
PE (1) PE20040499A1 (no)
PL (1) PL377679A1 (no)
RU (1) RU2310450C2 (no)
TW (1) TW200423941A (no)
UY (1) UY28038A1 (no)
WO (1) WO2004037289A2 (no)
ZA (1) ZA200501921B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
BRPI0515372B8 (pt) * 2004-09-17 2021-05-25 Durect Corp composição líquida para fornecer anestesia local prolongada após administração a um indivíduo, e, uso de bupivacaína, acetato isobutirato de sacarose e álcool benzílico
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
JP2008538751A (ja) * 2005-04-13 2008-11-06 ファイザー・プロダクツ・インク ナノ粒子組成物を持続放出するための注射用デポ製剤および方法
WO2006109177A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
EP1901722A4 (en) * 2005-06-20 2011-06-15 Elan Pharma Int Ltd NANOTEHOUS COMPOSITIONS WITH CONTROLLED RELEASE FROM ARYL-HETEROCYCLIC COMPOUNDS
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
KR100908517B1 (ko) * 2006-07-04 2009-07-20 (주)아모레퍼시픽 호흡기계 약제 전달을 위한 서방형 다공성 미세입자 및 그제조 방법
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
WO2009075782A1 (en) * 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US20110144202A1 (en) * 2008-06-16 2011-06-16 Uwe Marx Concentrated oxaliplatin solution and its method of preparation
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN104688686A (zh) * 2015-02-10 2015-06-10 万全万特制药江苏有限公司 一种含有齐拉西酮及其盐的脂肪乳注射剂
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
US10799289B2 (en) 2018-10-15 2020-10-13 Avent, Inc. Compositions, systems, kits, and methods for neural ablation
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029782A (en) * 1975-04-28 1977-06-14 Eli Lilly And Company Cefazolin suspension for parenteral administration
US4512986A (en) * 1983-07-26 1985-04-23 Research Triangle Institute Progrestationally active steroids
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JP2002512597A (ja) * 1996-12-20 2002-04-23 アルザ コーポレイション 注射可能な貯留槽ゲル組成物およびこの組成物の製造方法
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders
PL196867B1 (pl) * 1999-05-27 2008-02-29 Pfizer Prod Inc Kompozycja zyprazydonu
US6753011B2 (en) * 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
JP4334229B2 (ja) * 2001-03-20 2009-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers

Also Published As

Publication number Publication date
RU2310450C2 (ru) 2007-11-20
ZA200501921B (en) 2006-10-25
NL1024590C2 (nl) 2005-05-23
CN1849110A (zh) 2006-10-18
PL377679A1 (pl) 2006-02-06
JP2006514923A (ja) 2006-05-18
TW200423941A (en) 2004-11-16
BR0315568A (pt) 2005-08-23
RU2005112207A (ru) 2005-09-10
NL1024590A1 (nl) 2004-04-27
AR041722A1 (es) 2005-05-26
KR20050055781A (ko) 2005-06-13
WO2004037289A2 (en) 2004-05-06
US20040138237A1 (en) 2004-07-15
WO2004037289A3 (en) 2005-12-01
PA8586201A1 (es) 2004-09-16
CA2503076A1 (en) 2004-05-06
UY28038A1 (es) 2004-05-31
EP1575616A2 (en) 2005-09-21
AU2003267788A1 (en) 2004-05-13
PE20040499A1 (es) 2004-08-18
MXPA05002561A (es) 2005-05-05

Similar Documents

Publication Publication Date Title
BRPI0414539B8 (pt) composto, composição farmacêutica, e, uso de um composto
WO2004037289A3 (en) Novel injectable depot formulations
HRP20080564T3 (hr) Dihidrotetrabenazini i farmaceutski pripravci koji ih sadrže
BR0210139A (pt) Composições farmacêuticas
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
NO20072839L (no) 4-hydroksybenzomorfaner
BRPI0412684A (pt) compostos ppar-ativos
SV2004001432A (es) 2-tio-3,5-diciano-4-4fenil-6-aminopiridinas substituidas y su uso ref. lea 35 640-sv
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
DE50015623D1 (de) Kovalent verbrückte insulindimere
WO2002009758A3 (en) Inhibitors of cellular efflux pumps of microbes
NO20054083L (no) Nye sammenkoblede triazoloner og deres anvendelse
DE50313020D1 (de) Radialkolbenpumpe
NO20051187L (no) Depotformuleringer bestaende av aktive arylheterocykliske forbindelser i form av en suspensjon
NO20063393L (no) Farmasoytiske preparater
DE60101486D1 (de) Verwendung von Polyaminosäurederivate als Konservierungsmittel
NO20050019L (no) Polytylenglykolaldehyd-derivater
NO20040563L (no) Nye benzokondenserte heterocykler som endotelin antagonister.
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
UY28148A1 (es) Bromhidrato de escitalopram y un metodo para su preparacion
ATE382778T1 (de) Pumpenkombination
ES2530579T3 (es) Análogos de propofol, procedimiento para su preparación, y procedimientos de uso
ITRM20020477A1 (it) Procedimento per la realizzazione di un fantoccio stereolitografato biomorfo, multicompartimentale e per esami multianalitici, e relativo dispositivo.
BR0300315B1 (pt) montagem de cilindro de compressor hermético.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application